Evaluating Wharton’s jelly-derived stem cell therapy in autism:Insights from a case study  

作　　者：Muzamil Akhtar Abdulqadir J Nashwan 

机构地区：[1]College of Medicine,Gujranwala Medical College,Gujranwala 52250,Punjab,Pakistan [2]Department of Nursing and Midwifery Research,Hamad Medical Corporation,Doha 3050,Qatar

出　　处：《World Journal of Methodology》2025年第2期174-176,共3页世界方法学杂志（英文）

摘　　要：Autism spectrum disorder(ASD)is a complex neurodevelopmental disorder affecting over 2%of the global population,marked by social communication deficits and repetitive behaviors.Kabatas et al explored the efficacy and safety of Wharton’s jelly-derived mesenchymal stem cell(WJ-MSC)therapy in a 4-year-old child with ASD.Using the childhood autism rating scale and Denver II develop-mental screening test,significant improvements were seen after six WJ-MSC sessions,with no adverse events over 2 years.Despite promising results,the study’s single-case design limits generalizability.Larger,multi-center trials are needed to validate the findings and assess long-term effects of WJ-MSC therapy in ASD.

关 键 词：Autism spectrum disorder Stem cell therapy NEUROINFLAMMATION Neuro-developmental disorders Wharton jelly derived mesenchymal stem cell 

分 类 号：R747.2[医药卫生—神经病学与精神病学]